Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.

Also called NCT02791763

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 355 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02791763
Other papers using this trial's data
  • Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial American journal of nephrology, 2021 DOI, PubMed 33561857, PMC8117260 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02791763. Randomized; no masking; primary purpose treatment. Start 2016-06-06 (actual); primary completion 2018-10-26 (actual). Results posted on 2019-11-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
Condition
Anaemia
Intervention (Drug)
1 to 4 mg tablets of GSK1278863
Intervention (Drug)
6 mg GSK1278863 tablet
Intervention (Drug)
Epoetin beta pegol
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02791763
Content hash
deeadef1aa503de39e3923b38d2aa155020da6b0a8439802cfb95c70c8920e80